Biotech

All Articles

Amgen documents very first phase 3 win for $400M dermatitis medicine

.Amgen has discussed (PDF) the initial period 3 records on its own $400 thousand dermatitis medicati...

Biogen, UCB file phase 3 lupus succeed after stopping working earlier trial

.Biogen and also UCB's rely on improving right into period 3 on the back of an unsuccessful research...

Aptadir wishes brand new RNA inhibitors can easily turn around challenging cancers

.Italian biotech Aptadir Therapies has released along with the pledge that its own pipeline of precl...

Wave surfs DMD success to regulators' doors, sending out stockpile

.Surge Life Sciences has actually met its own target in a Duchenne muscle dystrophy (DMD) study, ins...

Sanofi picks brand-new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma layer, occup...

Achilles droplets cell therapy plan, prepares for unemployments after missing out on 'commercial stability' goals

.Achilles Rehabs has shreded its own approach. The British biotech is quiting working on its clinica...

Aligos declares period 2 MASH win, slashing liver excess fat around 46%

.Aligos Therapies is advertising a midstage gain in metabolic-dysfunction affiliated steatohepatitis...

Basilea scores $268M BARDA backing for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job developing brand-new antifungals has acquired a substantial increase co...

Capricor offers Europe legal rights to late-stage DMD therapy for $35M

.Having currently gathered up the USA liberties to Capricor Rehabs' late-stage Duchenne muscle dystr...

FDA junks adcomm for Applied's uncommon condition medication

.After dismissing the choice meeting for Applied Therapies' metabolic disorder drug govorestat, the ...